explore -WSS

explore

author：focus 2025-09-30 22:22:30 - browse：1733

Adam's take main illustration — Molly Ferguson/STAT

Cassava Sciences has long claimed its experimental drug, called simufilam, slows the cognitive decline of people with Alzheimer’s. On Friday, we learned how: The company recruited a large number of people into its clinical trial who don’t have Alzheimer’s.

People who almost certainly had Alzheimer’s were also included in the study, but in this group, a placebo outperformed Cassava’s drug.

The conclusion, of course, is obvious: Simufilam is inactive. It’s an inert compound no more effective than a placebo. Cassava’s assertion that simufilam is showing “disease-modifying activity” falls apart given its study was opened to people who should have been ineligible because they were misdiagnosed with Alzheimer’s. Whether that was done intentionally or unwittingly isn’t known, but it’s certainly troubling and makes the case for immediate, regulatory intervention even stronger.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Election results set back Medicaid expansion plans

leisure time

WSS

Doctors are clamoring for more clarity on Paxlovid prescribing

Paxlovid rebound happens. Why and to whom are still a mystery

Philadelphia mass shooting: Few answers in apparently random attack as suspect charged with murder

Failure, not just success, should guide future doctors

Suspect in Ukraine detonates explosives at a courthouse, killing himself and wounding 2 officers

Princess Kate attends Wimbledon with Roger Federer: See the photos

hotspot

explore

hotspot

Hollywood unions extend contract negotiations for actors

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

After affirmative action ruling, medical educators look to 'holistic review'

Doctors push to include dialysis machines in emergency stockpile

At least 13 dead in Texas as scorching temps continue

'Insanity': 4th of July mass shootings across US kill 13, injure more than 80

Hepatitis C has a cure — but many Americans still lack access to it

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

BioMarin wins approval for gene therapy to treat hemophilia A

City of Memphis, police chief oppose effort to delay lawsuit in Tyre Nichols case

knowledge

Restaurant meals are packed with calories, and we still keep eating them

Pennsylvania man bitten on the head by bear during attack in his garage

A fugitive mob suspect in Greece is betrayed by his passion for hometown Naples soccer champions

Philadelphia mass shooting: Few answers in apparently random attack as suspect charged with murder

McConnell is warmly embraced by Kentucky Republicans amid questions about his health

Biden's Plan B on student loan forgiveness relies on Higher Education Act: What to know

leisure time

leisure time

focus

hotspot